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ABSTRACT
The levels of naturally occurring IgG, IgG1 and IgG2
antibodies against polyvalent pneumococcal capsular
polysaccharide antigen (Pneurnovcx'") were com-
pared between atopic and nonatopic children with
different ages, 6-12 months and 1, 2, 3, 4, 5-9 and
10-15 years, by enzyme-linked immunosorbent
assay. Children with asthma, atopic dermatitis, food
allergy or a combination of these, and those having
serum IgE levels exceeding 50 IU/mL at 6-12 months
old and 100 IU/mL at more than 1-year-old were
included as atopic groups. Asymptomatic children
whose serum IgE levels were less than these atopic
standards and those not having detectable IgE anti-
bodies to Dermatophagoides farinae comprised the
nonatopic groups. Geometric mean levels of IgG and
IgG, antibodies against pneumococcal antigen in-
creased steadily with age, and that of IgG2 antibodies
was low until 3 years of age and then gradually
increased age-dependently up to 15 years of age.
The levels of IgG antibody as well as IgG1 and IgG2
antibodies were not significantly different between
atopic and nonatopic children in any age group. This
suggests that the immune response to the most
common bacterial pathogen in the respiratory tract
does not influence atopic status.
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INTRODUCTION
The increased prevalence of atopic diseases such as
asthma, pollenosis, and atopic dermatitis has been docu-
mented in many parts of the world over the past several
decodes.l? Several explanations for this phenomenon are
possible; for example, air-pollution, increased indoor
exposure to inhaled allergens, decreased ventilation in
modern dwellings, and dietary chonqes.:' A diminished
exposure to infection is speculated as promoting the
prevalence of atopic diseoses." There is evidence to
suggest that a predominant activation of Th1-like T-helper
cells in the course of recurrent viral or bacterial infections
including Mycobacterium tuberculosis might prevent the
proliferation of Th2 clones, resulting in decreased inci-
dence of allergic diseoses.v"
The incidence of pneumococcal pneumonia has
declined drastically during the past several decades in
developed countries. However, scarcely any data are
available regarding the influence of the pneumococcus
infection on atopic status. In this study, to further evaluate
the relations between antipneumoccal immunity and atopy,
we compared naturally occuring IgG, IgG 1, and IgG2
antibody levels against pneumococcal capsular poly-
saccharide antigen in a series of age-matched atopic and
nonatopic groups of children.
METHODS
Subjects
Atopic sera were obtained from patients aged 6 months
to 15 years who visited the Pediatric Allergy Clinic of the
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University Hospital of Tsukuba. The patients had either
asthma, atopic dermatitis, food allergies or a combina-
tion. A diagnosis of asthma was based on the definition
to the criteria of the National Institutes of Health, USA,
with minor rnodificctions.? Patients must have shown the
following characteristics: (i) recurrent episodes of wheez-
ing and shortness of breath during the past year; and
(ii) wheezing and dyspnea which was reversible, either
spontaneously or with bronchodilator treatment. Atopic
dermatitis was diagnosed based on the criteria estab-
lished in 1980 by Hanifin and Rajka.8 Children who
suffered episodes of anaphylactic reaction to the inges-
tion of food and showed an IgE antibody against the food
responsible were diagnosed with a food allergy. Non-
atopic sera were collected from two populations. In
younger children aged less than 6 years, sera were ob-
tained from patients with acute illness whose blood was
drawn for diagnostic purposes unrelated to allergy. In
older children aged 6 years or more, sera were collected
as part of an annual health check-up. The possibility of
allergic symptoms in these subjects was carefully exam-
ined by a pediatric allergist, and only children confirmed
by clinical history and physical examination as not having
allergic symptoms were selected for the groups. Parents
gave informed consent for their children to be included in
this study. Serum samples from atopic and nonatopic
children were divided into seven groups according to
age: 6-12 months and 1,2,3,4,5-9 and 10-15 years.
Serum IgE levels were determined by RIST kits (Pharmacia,
Uppsala Sweden). Specific IgE levels to Dermato-
phagoides farinae (D. farinae) were also measured using
the Pharmacia CAP system (Uppsala, Sweden). The sera
which had IgE levels exceeding 50 IU/ml in atopic chil-
dren aged 6-12 months and 100 IU/ml in children over
1 year of age were further selected for atopic sera, and
the sera which had IgE levels less than those atopic stan-
dards for age in nonatopic children and those not having
detectable IgE to D. farinae « 0.35 UA/ml) were
selected for nonatopic sera. Finally, 27-30 samples of
each age group were selected. The average total serum
IgE levels ± SE in atopic subjects aged 6-12 months
and 1, 2, 3, 4, 5-9 and 10-15 years, respectively, were
240 ± 40, 262 ± 29, 565 ± 105, 954 ± 182, 506 ±
71, 754 ± 91 and 1266 ± 297 IU/ml, and those in
nonatopic subjects were 12 ± 2, 37 ± 5, 38 ± 5,
27 ± 4,28 ± 5, 38 ± 5 and 43 ± 9, respectively. More
than 90% of subjects in each allergic group had asthma,
except infants aged 6-12 months and 1 year. No subject
had a history of prior pneumococcal immunization.
Antigen-specific ELISA
The assaywas performed as described previouslv.? Microtiter
plates (No. 69620, Nunc, Roskilde Denmark) were coated
overnight with 100 ilL/well of 1:100 diluted 23-valent pneu-
mococcal vaccine (Pneumovax®, Merck, Sharp & Dohme,
NJ, USA) that was dissolved in a carbonate coating buffer
(sodium carbonate/bicarbonate 0.1 mol/L, pH 9.6). The
plates were washed three times with washing buffer, (PBS
containing 0.1 % Tween 20). The buffer of the last wash was
left in the wells for 30 min to ensure complete inhibition of
non-specific binding. Blocking of C-polysaccharide (C-Ps,
Statens Seruminstitut, Copenhagen, Denmark) anti-bodies
was performed by adding 50 III of a 0.2% C-Ps solution to
1 ml serum diluted 1/25, as described by Koskelc.'? The
samples were incubated at 37°C for 2 h, then at 4°C
overnight and finally stored at -20°C. The sera were diluted
to 1:100, 1:25 and 1:50 in the IgG, IgG 1 and IgG2 assays,
respectively. On each plate the reference serum was tested
in eight two-fold dilutions starting at 1:100, 1:25 and 1:50
in the IgG, IgG 1 and IgG2 assays, respectively. A total of
100 III of the samples were applied to each well. The plates
were incubated for 1.5 h at room temperature, washed four
times, and 100 III of horseradish peroxidase (HRP)-conju-
gated antihuman IgG (Cappel, Durham, NC, USA), IgG 1
and IgG2 antibodies (Binding site, Birmingham, UK) diluted
to 1:2500, 1:250 and 1:500, respectively, were added. The
plates were incubated at room temperature for another
1.5 h, washed four times, and then 100 III of 0.2 mol/L
citrate-phosphate buffer (pH 5.0) containing 0.1 % (w/v.) 0-
phenylenediamine dihvdrochloride (OPD; Sigma Chemical
Company, St louis, MO, USA) and 0.01 % H202was added
to each well. After exactly 30 min, the reaction was stopped
by adding 50 III of 2 rnol/l, H2S04. The absorbance was
measured with an immunoreader (Japan Intermed Co. Ltd,
Tokyo, Japan) using a test wavelength of 490 nm and a ref-
erence wavelength of 630 nm.
As a reference on each plate, International Pneumo-
coccal Antibody Standard (PSAb90) consisting of a pool of
post-vaccination sera from 17 healthy adults (Carl E
Frasch, Center for Biologics, Evaluation and Research,
Food and Drug Administration, Washington, USA), was
assayed in eight two-fold dilutions starting at 1/100, 1/25
and 1/50 in the IgG, IgG 1 and IgG2 measurements, res-
pectively. The absorbancy at a serum dilution of 1:400 in
IgG, 1: 100 in IgG 1 and 1:200 in IgG2 was arbitrarily
defined as 320 ELISA units (EU)/ml, and IgG concen-
trations of the samples were quantitated by means of a
regression line calculated for the standard serum.
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Fig. 1. Comparison of (a) IgG, (b) IgG 1 and (c) IgG2 levels
against pneumococcal capsular polysaccharide antigen between
atopic (.) and nonatopic (0) children. Results are expressed as
the mean ELISA units ± SEM for each group including 29-30
subjects. The differences in IgG, IgG 1 and IgG2 levelsto pneumo-
coccus polysaccharide between atopic and nonatopic groups
were not significant (P > 0.05) in each age groups by Student's
t-test.
DISCUSSION
RESULTS
Statistical Analysis
Statistical analysis was performed using Student's t-test and
the Pearson's correlation coefficient by STATVIEW 4.1 on an
Apple Macintosh computer. Prevalence < 0.05 was con-
sidered significant.
The levels of IgG, IgG 1, and IgG2 antibodies against poly-
valent pneumococcal capsular polysaccharide antigen
were compared between atopic and nonatopic children in
different age groups. The distributions of IgG, IgG 1 and
IgG2 antibody levels against pneumococcal polysaccharide
in atopic and nonatopic children are shown in the Fig. 1
panels A, Band C, respectively. Geometric mean levels of
IgG and IgG 1 antibodies against pneumococcal antigen
increased steadily with age, and that of IgG2 antibodies
was low until 3 years of age and then gradually increased
age-dependently up to 15 years of age. Although atopic
children tended to have higher antibody levels against
pneumococcal polysaccharide than nonatopic children in
each age group, there were no significant differences
between any two age-matched groups (P > 0.05).
The levels of IgG, IgG 1, and IgG2 antibodies to poly-
valent pneumococcal capsular polysaccharide antigen
were compared in atopic and nonatopic groups by the
Pearson's correlation coefficient. The correlation coeffi-
cients between IgG and IgG 1, between IgG and IgG2 and
between IgG 1 and IgG2 in atopic groups were 0.50, 0.59
and 0.49 and those in nonatopic groups 0.62, 0.50 and
0.59, respectively. No significant difference was found in
comparison of correlation coefficients between atopic and
nonatopic groups (P > 0.05).
In this study, the levels of naturally occurring IgG, IgG 1,
and IgG2 antibodies against polyvalent pneumococcal
capsular polysaccharide antigens (Pneurnovox'") were
compared between atopic and nonatopic children in
age-matched groups. The results indicate that the levels
of IgG antibody as well as IgG 1 and IgG2 antibody are
not significantly different between atopic and nonatopic
children in any age group.
CD4 + T-helper cells, type 1 and type 2 (Th1 and Th2),
playa crucial role in facilitating immune responses." In
allergic responses, the Th2 subset of T cells is central in
mediating IgE production and in developing immediate
hypersensitivity.12,13 Shirakawa et 01. recently reported a
strong inverse association between delayed hypersensitivity
5-9 10-15
5-9 10-15
5-9 10-15
4
4
3
3
2
2
234
Age (years)
o
o
100
o
o ~'-I-.L_
o
100
300
200
500 (a)
200
400
300
500
300
500
400
(b)
600
400
(e)
600
--l
UJ
«
(/)
--l
E
?
200
100
] 86 E NOGUCHI ET AL.
to M. tuberculosis and atopy among Japanese school
children, suggesting that exposure to M. tuberculosis
may inhibit atopic disorders by promoting Th1 lmrnunity.?
Since the responses to pneumococcal antigen are thymus-
independent.I":" it is difficult to directly compare our
results with the thymus-dependent responses. However,
our findings suggest that the immune response to pneumo-
coccus, the common bacterial pathogen in the respiratory
tract, does not influence atopic status.
The pneumococcal capsular polysaccharide antigen
used, Pneurnovcx", includes multiple serotypes with poor,
intermediate, or good immunogenicity in infonts.!" It is
likely that high levels of anti-pneumococcal antibodies may
reflect a strong response to a particular serotype. However,
recent studies have shown that antibody titers against poly-
valent pneumococcal capsular antigens correlate well with
the resistance to pneumococcal infection. 18,19
Pneumococcal infection frequently follows a viral res-
piratory tract infection,2° which may produce mucosal
dorncqe." diminish the epithelial ciliary activity,22 and de-
pressthe function of the alveolar rnocrophcqes.P Asthmatic
patients also have damaged airway epithelium, often
accompanied by depressed ciliary function." Although no
significant difference was seen, the atopic children did
appear to have higher levels of pneumococcal antibody
titers than did the controls. This may be influenced by the fact
that more than 90% of our atopic children were asthmatics.
The present study did not show a significant associa-
tion between anti-pneumococcal immunity and allergy.
Further study is required to evaluate the role of infection
in the development of allergic diseases.
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